Thinly traded micro cap Neon Therapeutics (NTGN +9.9%) is up on average volume following the release of updated data from a Phase 1b clinical trial, NT-001, evaluating personalized neoantigen vaccine NEO-PV-01, combined with Bristol-Myers Squibb's (BMY -0.3%) Opdivo (nivolumab), in metastatic melanoma patients. The results were presented at AACR in Atlanta.
According to R&D chief Richard Gaynor, Ph.D., a new analysis of 36-week data showed that two post-vaccine markers, epitope spread and tumor pathology, "clearly associate with durable clinical benefit."
52-week results should be available mid-year.
Subscribe for full text news in your inbox